Gritgen Therapeutics Co., Ltd.
Wednesday, June 05, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 2
Gritgen Therapeutics is a clinical-stage AAV GTx-focused biotech. We have establised two propreitary AAV GTx technology platforms: High-efficiency AAV Expression Cassette Design Platform, and AAV Capsid Discovery Platform. Our portfolio consists of global first-in-class/best-in-class assets in the field of liver-targeting, CNS and ophthalmology. GS1196 and GS1126 are 2 assets for which we are seeking partners.
GS1196 is an AAV GTx designed to treat HAE, featuring high C1-INH expression efficiency which was validated in NHP model, where a dose of 1E13 vg/kg mediated 72 μg/mL of C1-INH, far exceeding competitors. This high level of C1-INH expression could deliver significant HAE attack reduction.
GS1126 is a first-in-class AAV GTx with unique dual mechanism treating PKU, which could inhibits mutant PAH gene expression and simultaneously reintroduces normal PAH gene to restore function. In preclinical model, GS1126 demonstrated much deeper and sustained Phe reduction than competitors.
Company Website:
https://www.gritgen.com/en
Lead Product in Development:
GS1191 is the first AAV gene therapy receiving IND approval by Chinese NMPA for severe Hemophilia A, with best-in-class potential to offer functional cures. We have completed patient recruitment in Phase 1 and will initiate Phase 2/3 pivotal trials in 24H2.
GS1196 is an AAV GTx designed to treat Hereditary Angiedema, featuring high C1-INH expression efficiency. This efficiency has been validated in NHP model, where a dose of 1E13 vg/kg mediated 72 μg/mL of C1-INH, significantly surpassing its competitors. This high level of C1-INH expression could potentially deliver significant HAE attack reduction. we will file IND of GS1196 to FDA in 24H2.
GS1126 is a first-in-class AAV GTx with unique dual mechanism treating PKU, which could inhibits mutant PAH gene expression and simultaneously reintroduces normal PAH gene to restore function. In preclinical model, GS1126 demonstrated much deeper and sustained Phe reduction than competitors. we will file IND of GS1126 to FDA in 24H2.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Suzhou
Company HQ State
Jiangsu
Company HQ Country
China
CEO/Top Company Official
CEO: Fenglan Wu
CTO: Guiyi Zhang
CMO: Changdong Liu
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())